UBS Global Healthcare Conference - BIO-RAD LABORATORIES INC

Financial Performance:

• Q3 2024 non-GAAP operating margin improved 100 bps YoY to 12.8%, driven by mix evolution (strong process chromatography and quality control) and structural efficiencies, though R&D spending was redirected.
• Q3 sales grew just under 1% in constant currency, marking a return to growth after a period of decline, with specific strength in Droplet Digital PCR (ddPCR) instruments up >20% for three consecutive quarters.
• Free Cash Flow (FCF) guidance remains $290–$340 million for the full year; YTD FCF was $210 million, with the Q3 dip attributed to one-time restructuring charges and investments that will not repeat in Q4.
• The company maintains a strong balance sheet with positive net cash and a monetizable stake in Sartorius.
• Targeting $30–$35 million in net annual savings ramping to completion by 2028, with benefits beginning to materialize in 2027.
• Process chromatography grew in Q3 but was depressed by customer inventory adjustments related to government vaccine policies; expected to return to mid-single-digit growth in 2027.

Guidance and Future Outlook:

• Management expects market headwinds to persist into 2027, with Q4 2024 expected to be a continuation of Q3 conditions rather than a marked improvement.
• Long-term margin target is mid-teens operating margin, to be achieved over the next two to three years as a milestone toward further expansion.
• Top-line growth goal is to return to market growth rates (historically 1.5–2%), driven by portfolio revitalization and execution; specific targets include mid-single digit growth for the Tools segment and high-single digit for process chromatography long-term.
• FCF expansion is a key focus area, alongside working capital optimization and rationalized CapEx to ensure returns on investment.
• The company anticipates a "trickle-down" effect where current biopharma funding eventually cascades into the discovery stage where Bio-Rad's portfolio is concentrated.

Business Segments and Product Lines:

• Life Sciences Tools (approx. 40% of revenue): ddPCR instruments led growth with 20%+ quarterly increases, fueled by the QX700 series and a fully integrated assay library (400,000+ assays from Stila Technologies acquisition).
• Process Chromatography: Currently facing demand softness due to vaccine policy changes, but positioned for recovery and high-single-digit growth as clinical programs migrate to commercial phases.
• Diagnostics: Grew 3% in Q3; includes market leadership in quality systems and immunohematology. Management is actively evaluating M&A and internal R&D to expand in molecular diagnostics and quality control (e.g., oncology applications).
• Geography: China represents ~6% of total sales; growth returned in Q3 due to local manufacturing capacity enabling participation in government tenders, though volatility is expected.
• Innovation: New imager technology released two quarters ahead of schedule, incorporating AI for image analysis in Western blot workflows.

Market and Competitive Landscape:

• End Markets: Large pharma and bioprocessing remain robust, while Academic & Government (A&G) funding faces geopolitical and budgetary headwinds, particularly in Europe and the US.
• Competition: Bio-Rad leverages its industry-leading assay library and AI-enhanced instruments to differentiate in the ddPCR space.
• Strategic Partnerships: Bio-Rad prefers strategic investments/partnerships (e.g., Genoscopy) to validate digital PCR in diagnostics rather than entering the Dx market directly, allowing for market validation while retaining core focus.
• AI Trends: AI is being integrated into products to enhance workflow efficiency and data insights (e.g., in silico analysis), though direct revenue impact from AI-driven new customers is still in early stages.

Risks and Challenges:

• Market Volatility: Persistent headwinds in A&G and geopolitical tensions in China could delay return to market growth rates.
• Clinical Phase Delays: Revenue from process chromatography depends on clinical programs successfully migrating to commercial stages.
• Consumable Pull-through: ddPCR instrument sales are strong, but consumable revenue lag is longer than the typical 6–12 months due to market softness, potentially impacting revenue recognition timing.
• Execution Risks: The company acknowledges a historical drag from M&A deals that did not perform as expected and is overhauling its acquisition strategy to focus on market-positioned assets with clear growth/margin synergy.

Management Commentary and Tone:

• Tone: Confident and transformational; management emphasizes a "new executive suite" driving foundational changes, R&D vitality, and operational discipline.
• Strategic Alignment: Management notes strong alignment with the investment community, including activist investor Elliott, regarding execution priorities and capital allocation.
• Focus Areas: The core narrative is shifting from "survival" to "acceleration" via R&D velocity, AI integration, and disciplined cost management.
• Capital Allocation: Emphasizes a "build, buy, or partner" approach, with a preference for internal R&D and targeted M&A over transformative deals, supported by a strong balance sheet.
• Sartorius Stake: Management downplays the operational impact of the Sartorius stake, viewing it primarily as a liquidity option and balance sheet asset rather than a core operational driver.

Analyst Questions and Answers:

• Growth Drivers: Analysts asked about the gap between recent low single-digit growth and market rates; Management attributed this to R&D execution, portfolio evolution, and the timing of new product introductions like the Stila acquisition.
• China Outlook: Questions regarding China focused on sustainability; Management confirmed a commitment to the market with new local manufacturing capacity to support government tenders.
• Margins: Analysts queried the sustainability of margin expansion; Management explained that the Q3 improvement was a mix of structural efficiencies and favorable product mix, with a clear path to mid-teens over 2-3 years.
• M&A Strategy: Questions on M&A revealed a shift from previous failed deals to a more disciplined approach focusing on tuck-ins and assets that accelerate growth/margins, particularly in diagnostics and quality control.
• Free Cash Flow: Analysts noted the FCF drop in Q3; Management confirmed the Q3 charges were non-recurring and reiterated the full-year guidance is achievable via Q4 momentum and working capital improvements.

Other Key Points:

• Stila Technologies: The acquisition of Stila was successful in integrating the QX700 instrument and its assay library within one year, creating a critical competitive differentiator in the ddPCR space.
• Restructuring: A significant one-time restructuring charge was taken in Q3 to reposition the organization for the future, with net savings expected to ramp by 2028.
• Product Velocity: The release of new imager technology two quarters ahead of schedule highlights an improvement in R&D execution and delivery speed compared to historical norms.
• Quality Controls: Identified as a fragmented market opportunity where Bio-Rad holds leadership; potential for expansion into new verticals (e.g., oncology) via internal R&D or M&A.
• Investor Relations: The call served to validate the company's turnaround story and reaffirm alignment with shareholders on the long-term value creation plan.